Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

Metagenomi Therapeutics (Nasdaq: MGX) announced that President and CEO Jian Irish, Ph.D., M.B.A., will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 7:35 a.m. ET.

Rhea-AI Summary

Metagenomi Therapeutics (Nasdaq: MGX) announced that President and CEO Jian Irish, Ph.D., M.B.A., will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 7:35 a.m. ET. The presentation will be accessible via the Investors section of the company’s website.

Argus May 28 session

+3.70% close to close Open Argus

Details

News Market Reaction – MGX

On May 28, the day this news came out, MGX closed 3.70% above the previous close.

Data tracked by StockTitan Argus for the May 28 session.

Market Context

This announcement highlights Metagenomi’s continued investor outreach, with its President and CEO pr...

Analysis

This announcement highlights Metagenomi’s continued investor outreach, with its President and CEO presenting at the Jefferies Global Healthcare Conference on June 4, 2026 at 7:35 a.m. ET. In recent months, the company emphasized cash runway into 4Q 2027, progress toward a 4Q 2026 IND for MGX-001, and peer-reviewed validation of its compact CRISPR nuclease. Investors may watch future updates on regulatory milestones, partnership activity, and conference disclosures for additional clarity.

Key Figures

Conference date: June 4, 2026 Presentation time: 7:35 a.m. ET Announcement date: May 28, 2026

Conference date

June 4, 2026

Jefferies Global Healthcare Conference fireside chat

Presentation time

7:35 a.m. ET

Scheduled start time of Jefferies fireside chat

Announcement date

May 28, 2026

Press release date for Jefferies conference participation

Historical Context

5 past events · Latest: May 11

5 events

1. May 11

   Earnings update

   24h Move

   +0.0%

   Reported Q1 2026 results, MGX-001 timelines, and cash runway through 4Q 2027.

2. Apr 16

   Scientific publication

   24h Move

   +0.0%

   Nature Structural & Molecular Biology paper on compact CRISPR nuclease MG119-28.

3. Mar 05

   Full-year earnings

   24h Move

   -8.1%

   Full-year 2025 results, MGX-001 pre-IND progress, and cash runway into 4Q 2027.

4. Feb 23

   Conference appearance

   24h Move

   +6.4%

   Announcement of fireside chat at 46th Annual TD Cowen Healthcare Conference.

5. Jan 12

   Corporate update

   24h Move

   -2.2%

   Corporate name change and milestones, including MGX-001 durability and 4Q 2026 IND/CTA plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

in vivo genome editing

1 terms

in vivo genome editing medical

"an in vivo genome editing company capitalizing on its proprietary technologies"

In vivo genome editing changes an organism's DNA inside the living body using molecular tools that cut, alter or replace short stretches of genetic code—much like editing a sentence in a book while it remains on the shelf. It matters to investors because successful in vivo edits can produce one-time, potentially curative therapies and large market opportunities, but they also bring high technical, safety and regulatory risks that influence clinical success, approval timing and long-term value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 4, 2026, at 7:35 a.m. ET.

The fireside chat presentation will be made available on the “News & Events” page in the Investors section of the Company’s website at https://ir.metagenomi.co/news-events/events.

About Metagenomi Therapeutics

Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel CRISPR gene-editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, insertion and correction.

MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile with best-in-class treatment potential, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children, potentially enabling a new standard of care for the treatment of hemophilia A. The Company is also currently pursuing indications leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co/. 

Investor Contact:

Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Metagenomi Therapeutics (MGX) present at the Jefferies Global Healthcare Conference?

Metagenomi Therapeutics will participate in a fireside chat on June 4, 2026, at 7:35 a.m. ET. According to Metagenomi, the event is part of the Jefferies Global Healthcare Conference in New York, offering investors insights into its in vivo genome editing platform.

Who will represent Metagenomi Therapeutics (MGX) at the Jefferies Global Healthcare Conference?

Metagenomi Therapeutics will be represented by Jian Irish, Ph.D., M.B.A., President and CEO, in a fireside chat. According to Metagenomi, Irish will discuss the company’s in vivo genome editing approach and progress in developing curative genetic medicines for patients.

How can investors access Metagenomi Therapeutics’ Jefferies Global Healthcare Conference presentation?

Investors can access the fireside chat presentation via the “News & Events” page in the Investors section of Metagenomi’s website. According to Metagenomi, the webcast link will be posted at https://ir.metagenomi.co/news-events/events for convenient online viewing.

What type of event is Metagenomi Therapeutics (MGX) hosting at the Jefferies Global Healthcare Conference?

Metagenomi Therapeutics is hosting a fireside chat discussion at the conference. According to Metagenomi, this informal format allows leadership to highlight its proprietary in vivo genome editing technologies and strategic vision for creating curative genetic medicines for patients.

Where is the Jefferies Global Healthcare Conference featuring Metagenomi Therapeutics (MGX) being held?

The Jefferies Global Healthcare Conference featuring Metagenomi’s fireside chat will be held in New York, NY. According to Metagenomi, the session with President and CEO Jian Irish is scheduled for June 4, 2026, at 7:35 a.m. Eastern Time.